Trial
NCT04684914
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Altimmune, Inc.
Collaborators
—
Condition
Hepatitis B, Chronic
Intervention
HepTcell
Why stopped
Did not meet endpoints
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-08